CNS Pharmaceuticals, Inc. (CNSP)
NASDAQ: CNSP · IEX Real-Time Price · USD
0.216
-0.001 (-0.64%)
At close: May 31, 2024, 4:00 PM
0.210
-0.006 (-2.87%)
After-hours: May 31, 2024, 5:40 PM EDT
Company Description
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors.
The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.
CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D.
Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
CNS Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Nov 8, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | John Michael Climaco Esq., J.D. |
Contact Details
Address: 2100 West Loop South, Suite 900 Houston, Texas 77027 United States | |
| Phone | 1-800-946-9185 |
| Website | cnspharma.com |
Stock Details
| Ticker Symbol | CNSP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001729427 |
| CUSIP Number | 18978H102 |
| ISIN Number | US18978H2013 |
| Employer ID | 82-2318545 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John Michael Climaco Esq., J.D. | Chief Executive Officer, President and Director |
| Christopher S. Downs C.P.A., CTP, FP&A | Chief Financial Officer |
| Dr. Sandra L. Silberman M.D., Ph.D. | Chief Medical Officer |
| Dr. Waldemar Priebe Ph.D. | Founder |
| Dr. Donald H. Picker Ph.D. | Chief Science Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 17, 2024 | EFFECT | Notice of Effectiveness |
| May 16, 2024 | 8-K | Current Report |
| May 15, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| May 7, 2024 | 8-K | Current Report |
| May 3, 2024 | 8-K | Current Report |
| Apr 15, 2024 | 8-K | Current Report |
| Apr 10, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2024 | 8-K | Current Report |
| Apr 1, 2024 | 10-K | Annual Report |